The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]
, 2020 Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M +6 more
core
CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. [PDF]
, 2019 Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a genetically heterogeneous subtype of B-cell ALL characterized by chromosomal rearrangements and mutations that result in aberrant cytokine receptor and kinase signaling.
Delgado-Martin, Cristina +5 more
core +2 more sources
JAK2 Negative Polycythemia Vera
Journal of Laboratory Physicians, 2010 ABSTRACTPolycythemia vera (PV) is a stem cell disorder, characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Several reasons suggest that a mutation on the Janus kinase-2 gene (JAK2) is the most probable candidate gene involved in PV pathogenesis, as JAK2 is directly involved in intracellular signaling, following its exposure ...
Geetha, J P +3 more
openaire +2 more sources
CALRETICULIN IN MYELOPROLIFERATIVE NEOPLASMS: THE OTHER SIDE OF THE ALICE MIRROR [PDF]
European Medical Journal Hematology, 2014 Calreticulin (CALR), a Ca2+ binding protein mostly localised in the endoplasmic reticulum, regulates Ca2+ homeostasis, chaperones, and other proteins to the nucleus and other cellular compartments.
Lilian Varricchio, Anna Rita Migliaccio
doaj
Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. [PDF]
PLoS ONE, 2010 Given the importance of Jak2 in cell signaling, a critical role for Jak2 in immune cells especially dendritic cells (DCs) has long been proposed.
Jixin Zhong +6 more
doaj +1 more source
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]
, 2018 The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T +13 more
core +2 more sources
Therapeutic potential of JAK2 inhibitors [PDF]
Hematology, 2009 AbstractThe discovery of an activating tyrosine kinase mutation JAK2V617F in myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has resulted in the development of JAK2 inhibitors, of which several are being evaluated in phase I/II clinical studies.
openaire +2 more sources
t(9;9)(p13;p24) PAX5/JAK2 - del(9)(p13p24) PAX5/JAK2 - inv(9)(p13p24) PAX5/JAK2 [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2014 Short communication on t(9;9)(p13;p24) PAX5/JAK2, with data on clinics, and the genes implicated.
openaire +2 more sources
Aging Is a Key Driver for Adult Acute Myeloid Leukemia
Aging and Cancer, EarlyView.Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley +1 more source
Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis
Avicenna Journal of Medicine, 2014 Hepatosplenic T-cell lymphoma (HSTL) is a rare T-cell neoplasm of the lymphoid system. This type of lymphoma is characterized by sinusoidal infiltration of spleen, liver, bone marrow and lymph nodes by neoplastic lymphocytes.
Ali M Gabali +4 more
doaj +1 more source